Compelling evidence suggests that IL-6 derived from CAFs mediates therapeutic resistance, including chemoresistance by upregulating CXCR7 expression via STAT3/NF-κb pathway in ESCC [62], and IL-6 blockade improves checkpoint blockade therapy and promotes tumor immunity [63]. The gene discussed is IL6; the disease is neoplasm.